<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04938843</url>
  </required_header>
  <id_info>
    <org_study_id>META003</org_study_id>
    <nct_id>NCT04938843</nct_id>
  </id_info>
  <brief_title>Effect of F. Prausnitzii on Glycemic Control</brief_title>
  <official_title>Effect of F. Prausnitzii on Glycemic Control - a Randomized, Double Blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetaboGen AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MetaboGen AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The microbiota is associated with a wide spectrum of diseases including diabetes and&#xD;
      non-alcoholic fatty liver disease. In this study we will investigate if the bacteria F.&#xD;
      prausnitzii, which is a part of the human gut microbiota, can improve metabolic parameters in&#xD;
      subjects with impaired glucose control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blind, placebo-controlled study. Subjects with impaired glucose&#xD;
      control will after signing the informed consent and fulfilling the study criteria be&#xD;
      randomized to study product or placebo. The randomization ratio between the study product (F.&#xD;
      prausnitzii 1E8-5x1E8 CFU and D. piger) and placebo is 1:1. In total 176 subjects will be&#xD;
      randomized in the study.&#xD;
&#xD;
      The study will start with a Run-in period i.e. all the subjects will be given placebo&#xD;
      capsules. The subjects fulfilling the inclusion and exclusion criteria will be randomized at&#xD;
      Visit 2 to either study product or placebo in the ration 1:1. The treatment will last for 12&#xD;
      weeks, from Visit 2 to Visit 6. The study is ended with a 2-week period of follow up after&#xD;
      the final dose.&#xD;
&#xD;
      Blood samples are taken at Visits 1-4 and Visits 6-7. Feces samples are collected at Visit&#xD;
      2-7. One additional fecal sample will be sent by mail approximately one week after Visit 1.&#xD;
      Glucose monitoring (CGM) will be initiated at Visit 1 and Visit 5 and followed for 10 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in time (%) glucose concentration range of 3.5-6.0 mmol/L measured with continuous glucose monitoring (CGM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose levels</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in fp-glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in b-HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic Model Assessment (HOMA) for Insulin Resistance (IR)</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous glucose monitoring (CGM) mean</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in CGM mean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM SD</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in CGM SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM CV</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in CGM CV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM MAGE</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in CGM MAGE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose levels</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in CGM time (%) glucose concentration ≥7.0 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fat content</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in liver fat measured by transient elastography and given as CAP (continous attenuation parameter) in db/m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fat content</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in liver fat measured by ultrasound (kPa)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fat function test AST</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in AST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fat function test ALT</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fat function test GGT</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Change in GGT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Pre Diabetes</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>F. prausnitzii and D. piger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 capsule administered once daily 45 minutes before breakfast for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule administered once daily 45 minutes before breakfast for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>F. prausnitzii and D. piger</intervention_name>
    <description>Dietary supplementation with capsules containing F. prausnitzii and D. piger once daily for 12 consecutive weeks</description>
    <arm_group_label>F. prausnitzii and D. piger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dietary supplementation with placebo capsules identical to those containing F. prausnitzii and D. piger once daily for 12 consecutive weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent to participate in the study&#xD;
&#xD;
          -  Man or woman 50-75 years of age&#xD;
&#xD;
          -  Impaired glucose tolerance (IGT; capillary b-glucose 8.9-12.1 mmol/L, 120 minutes&#xD;
             after OGTT), impaired fasting glucose (IFG; capillary b-glucose 6.1-6.9 mmol/L) or&#xD;
             combined glucose intolerance (CGI, i.e. IFG and IGT)&#xD;
&#xD;
          -  Weight stable ±5 kg for the last 3 months, BMI &gt;18 kg/m2&#xD;
&#xD;
          -  Willingness and possibility to come to the planned study visits, use the Diary and&#xD;
             eQuestionnaires as well as follow the study instructions&#xD;
&#xD;
          -  Understand Swedish in speech and writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other reasons for liver inflammation e.g. hepatitis A, hepatitis B, hepatitis C,&#xD;
             HIV-positive, confirmed or suspected cirrhosis, Wilsons disease, autoimmune hepatitis,&#xD;
             hemochromatosis, alcohol related fatty liver or pancreatitis, laboratory screen&#xD;
             AST/ALT &gt;2 (ULN), Bilirubin &gt;1 (ULN)&#xD;
&#xD;
          -  Heart failure NYHA class III, cardiovascular event within 6 months, unstable angina&#xD;
             pectoris&#xD;
&#xD;
          -  Diabetes mellitus, HbA1c &gt;47 mmol/mol or fp-Glucose &gt;6.9 mmol/L on 2 occasions&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease and asthma treated with intermittent steroids to&#xD;
             be under control&#xD;
&#xD;
          -  Blood pressure &gt;170/105 mmHg&#xD;
&#xD;
          -  Blood donation &gt;500 mL blood &lt;3 months before screening&#xD;
&#xD;
          -  Anemia, Hb &lt;117 g/L females and Hb &lt;134 g/L males; leukopenia, LPK &lt;3.5x1E9/L, ongoing&#xD;
             infection CRP &gt;10 mg/L&#xD;
&#xD;
          -  Hyperthyroidism, T4 &gt;22 nmol/L or hypothyroidism, TSH &gt;4,2 mIU/L&#xD;
&#xD;
          -  Laboratory result of clinical significance meaning that participation in the study is&#xD;
             unsuitable according to Investigator&#xD;
&#xD;
          -  Calculated glomerular filtration rate (GFR) &lt;60 mL/min/1.73 m2&#xD;
&#xD;
          -  Cancer &lt;5 years since diagnosis, except for basal-cell carcinoma&#xD;
&#xD;
          -  Treatment during the last 3 months with oral steroids, biological drugs,&#xD;
             immunosuppressive drugs, e.g. cyklosporin, drugs known to cause liver damage or to be&#xD;
             liver toxic&#xD;
&#xD;
          -  Bariatric surgery&#xD;
&#xD;
          -  Antibiotic treatment during the last 3 months or reoccurring antibiotic treatment &gt;3&#xD;
             times a year&#xD;
&#xD;
          -  Regular or sporadic use of probiotic product (not food containing probiotics) during&#xD;
             the last 3 months&#xD;
&#xD;
          -  Confirmed IBD, irritable bowel syndrome (IBS), bile acid malabsorption,&#xD;
             gastrointestinal infections during the last 3 months or any experienced problems from&#xD;
             the gastrointestinal tract during the last month that the Investigator expect could&#xD;
             influence the participation in the study&#xD;
&#xD;
          -  Allergy to metronidazol, the adhesive glue for the CGM sensor, milk protein&#xD;
&#xD;
          -  Smoking &gt;10 cigarettes/day&#xD;
&#xD;
          -  Alcohol consumption, &gt;7 units/week females, &gt;14 units/week males&#xD;
&#xD;
          -  Use of narcotics e.g. cannabis, amphetamine (not medical use), hallucinogens,&#xD;
             gamma-hydroxybutyric acid&#xD;
&#xD;
          -  Pregnancy, breast-feeding or planned pregnancy&#xD;
&#xD;
          -  Participation in other studies except IGT2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanns-Ulrich Marschall</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wallenberg Laborotory, University of Gothenburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Maclus, PhD</last_name>
    <phone>+46 705823222</phone>
    <email>sara.malcus@metabogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wallenberg Laboratory, University of Gothenburg</name>
      <address>
        <city>Gothenburg</city>
        <state>Västra Götaland</state>
        <zip>413 50</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hanns-Ulrich Marschall, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Faecalibacterium prausnitzii</keyword>
  <keyword>Desulfovibrio piger</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

